Akebia Therapeutics Inc (NASDAQ: AKBA) on Friday, soared 1.05% from the previous trading day, before settling in for the closing price of $1.90. Within the past 52 weeks, AKBA’s price has moved between $0.80 and $2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -8.86% annually for the last half of the decade. The company achieved an average annual earnings per share of -1.19%. With a float of $207.61 million, this company’s outstanding shares have now reached $211.54 million.
In an organization with 167 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Akebia Therapeutics Inc is 4.85%, while institutional ownership is 24.86%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1.19% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Akebia Therapeutics Inc (AKBA) is currently performing well based on its current performance indicators. A quick ratio of 1.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.92 million. That was better than the volume of 1.89 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.34%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 73.40%, which indicates a significant decrease from 76.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.39% in the past 14 days, which was lower than the 56.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8703, while its 200-day Moving Average is $1.4634. However, in the short run, Akebia Therapeutics Inc’s stock first resistance to watch stands at $1.9500. Second resistance stands at $1.9800. The third major resistance level sits at $2.0200. If the price goes on to break the first support level at $1.8800, it is likely to go to the next support level at $1.8400. Assuming the price breaks the second support level, the third support level stands at $1.8100.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
Market capitalization of the company is 423.32 million based on 218,181K outstanding shares. Right now, sales total 194,620 K and income totals -51,930 K. The company made 37,430 K in profit during its latest quarter, and -20,040 K in sales during its previous quarter.
